Review Article
BRAF mutant non-small cell lung cancer and treatment with BRAF inhibitors
José Miguel Sánchez-Torres1, Santiago Viteri2, Miguel Angel Molina3, Rafael Rosell3,4
1
Hospital Universitario de la Princesa, Madrid, Spain; 2Quirón Dexeus University Hospital, Barcelona, Spain; 3Breakthrough Cancer Research Unit,
Pangaea Biotech S.L, Barcelona, Spain; 4Catalan Institute of Oncology, Badalona, Spain
Corresponding to: José Miguel Sánchez-Torres, M.D. Hospital Universitario de la Princesa, C/Diego de Leon, 62, 28006 Madrid, Spain. Email: jmiguelst@gmail.com.
Abstract: Inhibitors targeting active protein kinases, such as EGFR or ALK, have demonstrated significant efficacy in the treatment of lung cancer. Activating mutations in the MAPK pathway, which includes the enzymes RAS, RAF, MEK, and ERK, result in constitutive signalling, leading to oncogenic cell proliferation and escape from apoptosis; therefore this pathway is a focus of crucial interest for the development of cancer drugs. In melanoma, the most commonly mutated gene is BRAF, with mutations usually occurring in about 50% of all tumours. The BRAF Val600Glu (V600E) mutation constitutes more than 90% of mutations in melanoma. V600E BRAF mutation shows a great dependency on MEK activity, and offers a rational therapeutic strategy for this genetically defined tumour subtype. The use of vemurafenib and dabrafenib, agents that block MAPK signaling in patients with melanoma and the BRAF V600E mutation, has been associated with prolonged survival and progression-free survival. The frequency of V600E BRAF mutation in lung adenocarcinoma is 1.5% to 2.8%. Treatment of V600E BRAF-mutant lung adenocarcinomas with dabrafenib is under evaluation in a phase 2 trial, and could represent another milestone in individualized therapy for lung cancer patients. The next step will be a combination therapy of BRAF inhibitor dabrafenib and MEK inhibitor trametinib.
Key Words: Non-small cell lung cancer (NSCLC); BRAF mutations; individualized treatment
Submitted Mar 10, 2013. Accepted for publication Apr 15, 2013.doi: 10.3978/j.issn.2218-6751.2013.04.01
Scan to your mobile device or view this article at:

doc.guandang.net
Introduction
The mitogen-activated protein kinase (MAPK) kinase (MEKK)/extracellular signal-regulated kinase (ERK) cascades are membrane-to-nucleus signaling modules highly conserved from yeast to vertebrates and involved in multiple physiological processes. The RAS-RAF-MEK-ERK kinase pathway mediates cellular responses to growth signals (1). BRAF is a member of the RAF family of serine/threonine protein kinases. There are three RAF isoforms in humans: ARAF, BRAF, and CRAF (also called Raf-1). These serine/threonine protein kinases are components of a conserved signaling pathway downstream of the membrane-bound small G protein RAS, which is activated by growth factors, hormones, and cytokines (2). RAS stimulates and recruits RAF proteins to the cell membrane where they are activated (3). Active BRAF then activates a second protein kinase called MEK, which in turn activates a third protein kinase called ERK. Once activated, ERK can translocate into the nucleus where phosphorylates transcription factors, thereby regulating their activity (Figure 1). ERK regulates gene expression, cytoskeletal rearrangements, and metabolism to coordinate responses to extracellular signals and regulate proliferation, differentiation, angiogenesis, senescence, and apoptosis.
The three RAF proteins are not equal in their ability to activate MEK. A-RAF is a poor MEK activator. BRAF has been identified as the major MEK activator, and displays higher affinity for MEK1 and MEK2 than RAF-1 (4). The
BRAF and PIK3CA in 861 patients with non-small cell lung cancer Jianping...function, have been approved by the US FDA for the treatment of NSCLC ...
treatment of BRAF mutation-positive metastatic melanoma and anti-EGFR tyrosine...A small step towards personalized medicine for non-small cell lung cancer. ...
SCLC转化 11% 2% 3% 23% 机制不明确 BRAF EMT T790M 2% 5% 5% 机制...treatment Tax/Anthra capecitabine Non-small cell lung cancer ovarian cancer ...
Cell Carcinoma BRAF mutation NRAS mutation HER2 mutation RET translocation ... USA The treatment and diagnosis of non-small cell lung cancer (NSCLC) ...
Roughly half the mutant EGFR cases with acquired ...In the future, patient-specific treatment approach...non-small-cell lung cancer harbouring epidermal ...
inhibitor PLX4032/ vemurafenib for the treatment of BRAF mutant metastatic ...Abbreviations: NSCLC, non-small cell lung cancer; CRC, colorectal cancer; ...
biologically based treatment of EGFR-mutant non-small-cell lung cancer〔J〕...transactivate RAF dimmers and ERK signalling in cells with wild-type BRAF ...
primary end point: rate of treatment completion ...方法:液向芯片法 EGFR、 KRAS、 BRAF、 PIK3CA ...with stage III non-small cell lung cancer Part ...
Gene AKT1 ALK BRAF DDR2 EGFR FGFR1 HER2 KRAS MEK1 METa NRAS PIK3CA ...non-small cell lung cancer non-small cell lung cancer Head and Neck ...
热门文档